Can Johnson & Johnson Sustain Its Growth in 2017?

Can Johnson & Johnson Sustain Its Growth in 2017?


Yet although the stock performed well in 2016, gaining 15% for the year, J&J shares lost ground in the second half of the year. Now, some investors are worried that harsher drug-pricing regulations could eat into profits in what has been J&J's biggest source of growth recently.



from Biotech News